Volume 7, Issue 3 (7-2019)                   J. Pediatr. Rev 2019, 7(3): 129-140 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Masoumi B, Eslami G, Alizadeh-Navaei R, Mondal P, Rezai M S. Safety Profile of Using Ciprofloxacin in Paediatrics: A Systematic Review and Meta-Analysis. J. Pediatr. Rev. 2019; 7 (3) :129-140
URL: http://jpr.mazums.ac.ir/article-1-203-en.html
1- Paediatric Infectious Diseases Research Centre, Mazandaran University of Medical Sciences, Sari, Iran.
2- Department of Clinical Pharmacy, Faculty of Pharmacy, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
3- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
4- Department of Paediatrics, Division of Pulmonary, Penn State College of Medicine, Hershey, Pennsylvania, USA.
5- Paediatric Infectious Diseases Research Centre, Mazandaran University of Medical Sciences, Sari, Iran. , rezai@mazums.ac.ir
Abstract:   (2045 Views)
Context: The use of ciprofloxacin is contraindicated in children due to safety concerns. Animal studies have revealed that ciprofloxacin can be associated with arthropathy (joint toxicity) in juvenile animals; however, this potential side effect has not been proven in children. Many clinicians still prescribe ciprofloxacin when there is no suitable alternative. In many developing countries, access to the newer generation of antibiotics is either limited or expensive. Therefore, ciprofloxacin is an available and cost-effective alternative that can save lives when necessary.
Objective: This study aimed to systemically review the published studies about the safety profile of using ciprofloxacin in children.
Data Sources: All relevant studies published from 1990 to 2018 in the Cochrane library, Trip database, ScienceDirect, PubMed, and Google Scholar were collected.
Study Selection: We have only considered clinical trials, which included the following keywords: “ciprofloxacin”, “children under 18 years”, and “arthropathy”. 
Data Extraction: The collected data were analyzed by Comprehensive Meta-Analysis software (CMA.2). We used random or fixed-effect methods based on the heterogeneity of the results. The heterogeneity was checked by I2 index and tau-squared. The publication bias was evaluated by the Begg’s test.
Results: The obtained data indicated no increased risk of arthropathy after ciprofloxacin use in children on a short-term basis, in comparison to placebo or other antibiotics.
Conclusions: Ciprofloxacin is potentially a safe alternative to be used in children under 18 years old when there is no better alternative. 
Full-Text [PDF 471 kb]   (656 Downloads) |   |   Full-Text (HTML)  (202 Views)  
Type of Study: Meta-analysis Review | Subject: Pediatric infection disease
Received: 2018/08/28 | Accepted: 2018/10/17 | Published: 2019/07/1

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2019 All Rights Reserved | Journal of Pediatrics Review

Designed & Developed by : Yektaweb